The current stock price of KMDA is 7.09 USD. In the past month the price increased by 4.26%. In the past year, price increased by 19.86%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
KAMADA LTD
2 Holtzman St., Science Park
Rehovot 7670402 IL
CEO: Amir London
Employees: 374
Phone: 97289406472
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
The current stock price of KMDA is 7.09 USD. The price increased by 0.28% in the last trading session.
KAMADA LTD (KMDA) has a dividend yield of 2.75%. The yearly dividend amount is currently 0.
KMDA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KMDA.
The Revenue of KAMADA LTD (KMDA) is expected to grow by 12.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
KAMADA LTD (KMDA) currently has 374 employees.
ChartMill assigns a technical rating of 8 / 10 to KMDA. When comparing the yearly performance of all stocks, KMDA is one of the better performing stocks in the market, outperforming 75.81% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to KMDA. KMDA scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months KMDA reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 28.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.7% | ||
| ROA | 5.42% | ||
| ROE | 7.71% | ||
| Debt/Equity | 0.04 |
9 analysts have analysed KMDA and the average price target is 15.05 USD. This implies a price increase of 112.2% is expected in the next year compared to the current price of 7.09.
For the next year, analysts expect an EPS growth of 41.23% and a revenue growth 12.48% for KMDA